Key Segmentation:
By Test Type
-
Rheumatoid Factor (RF)
-
Anti-Cyclic Citrullinated Peptide (Anti-CCP)
-
Erythrocyte Sedimentation Rate (ESR)
-
C-Reactive Protein (CRP)
-
Antinuclear Antibody (ANA)
-
Multi-Biomarker Panels
-
Other Tests
By Technology
-
Enzyme-Linked Immunosorbent Assay (ELISA)
-
Chemiluminescence Immunoassay (CLIA)
-
Immunoturbidimetry & Nephelometry
-
Multiplex Immunoassays
-
Molecular & Genomic Tests
By End User
-
Diagnostic Laboratories
-
Hospitals & Clinics
-
Specialty Rheumatology Clinics
-
Other End Users
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Test Type X End User)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
Key players include Abbott Laboratories, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Exagen Inc., and Augurex Life Sciences Corp., among others.
Key opportunities include novel biomarkers for seronegative RA, molecular tests predicting biologic therapy response, and expanding laboratory infrastructure in Asia-Pacific and Latin America.
The primary growth factor is the rising global prevalence of rheumatoid arthritis, combined with guideline-driven focus on early diagnosis to prevent irreversible joint damage.
By test type, the Anti-CCP segment dominates the Rheumatoid Arthritis Diagnostic Tests Market with approximately 27.64% share in 2025.
North America dominates the Rheumatoid Arthritis Diagnostic Tests Market with approximately 40.86% share in 2025.